Table 3 NNH for frequently occurring TEAEs (>5 %) in patients treated with droxidopa during randomized treatment
TEAE | NOH301/302 | NOH306 | Pooled | |||
|---|---|---|---|---|---|---|
Droxidopa (n = 131) | Placebo (n = 132) | Droxidopa (n = 114) | Placebo (n = 108) | Droxidopa (n = 245) | Placebo (n = 240) | |
Headache, n (%) | 8 (6.1) | 4 (3.0) | 15 (13.2) | 8 (7.4) | 23 (9.4) | 12 (5.0) |
NNH (95 % CI) | 33 (NS) | 18 (NS) | 23 (NS) | |||
Dizziness, n (%) | 5 (3.8) | 2 (1.5) | 11 (9.6) | 5 (4.6) | 16 (6.5) | 7 (2.9) |
NNH (95 % CI) | 44 (NS) | 20 (NS) | 28 (NS) | |||
Nausea, n (%) | 2 (1.5) | 2 (1.5) | 10 (8.8) | 5 (4.6) | 12 (4.9) | 7 (2.9) |
NNH (95 % CI) | 8647 (NS) | 20 (NS) | 51 (NS) | |||
Fatigue, n (%) | 2 (1.5) | 3 (2.3) | 8 (7.0) | 6 (5.6) | 10 (4.1) | 9 (3.8) |
NNH (95 % CI) | –135 (NS) | 69 (NS) | 302 (NS) | |||
Hypertension, n (%) | 2 (1.5) | 0 | 8 (7.0) | 1 (0.9) | 10 (4.1) | 1 (0.4) |
NNH (95 % CI) | 66 (NS) | 17 (NS) | 28 (15.9–94.6) | |||